Medical marijuana stocks have been all the rage and CARA has been lumped into that category, but the story is much deeper. Dr. Derek Chalmer, CEO of Cara Therapeutics joins Jill Malandrino at the NASDAQ MarketSite to give a complete review of the company. The company's lead program is an opiate-based program with the promise of analgesia with no narcotic side effects. CARA's main focus is obtaining approval for the first medications for 2016.

More from Video

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Will Tesla CEO Elon Musk Really Pulverize the Haters?

Will Tesla CEO Elon Musk Really Pulverize the Haters?

Jim Cramer's Investing Rule #4: Buy Damaged Stocks, Not Damaged Companies

Jim Cramer's Investing Rule #4: Buy Damaged Stocks, Not Damaged Companies

Jim Cramer's Investing Rule #3: Don't Buy Stocks All at Once

Jim Cramer's Investing Rule #3: Don't Buy Stocks All at Once